Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-02-15

FDA Approved: FOLOTYN — Supplemental Application (Acrotech Biopharma Inc)

View source ↗

Summary

FDA approved a supplemental application for Folotyn (pralatrexate) submitted by Acrotech Biopharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Folotyn (pralatrexate)

Snippet

SUPPL AP for FOLOTYN (PRALATREXATE)